Total Payments
$255,265
2024 Payments
$36,936
Companies
17
Transactions
177
Medicare Patients
274
Medicare Billing
$122,164
Payment Breakdown by Category
Consulting$153,546 (60.2%)
Travel$43,661 (17.1%)
Other$39,977 (15.7%)
Food & Beverage$14,881 (5.8%)
Research$3,200 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $153,546 | 41 | 60.2% |
| Travel and Lodging | $43,661 | 50 | 17.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21,780 | 7 | 8.5% |
| Honoraria | $18,196 | 6 | 7.1% |
| Food and Beverage | $14,881 | 72 | 5.8% |
| Unspecified | $3,200 | 1 | 1.3% |
Payments by Type
General
$252,065
176 transactions
Research
$3,200
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Shionogi Inc | $58,487 | 54 | $0 (2024) |
| PFIZER INC. | $48,888 | 12 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $40,151 | 38 | $0 (2021) |
| CSL Behring | $24,888 | 7 | $0 (2024) |
| Accelerate Diagnostics Inc. | $18,774 | 10 | $0 (2019) |
| GlaxoSmithKline, LLC. | $14,537 | 15 | $0 (2024) |
| BioFire Diagnostics, LLC | $12,206 | 5 | $0 (2020) |
| Roche Products Limited | $11,883 | 5 | $0 (2017) |
| La Jolla Pharmaceutical Company | $8,518 | 5 | $0 (2024) |
| Melinta Therapeutics, Inc. | $5,623 | 4 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $36,936 | 14 | CSL Behring ($24,888) |
| 2023 | $16,764 | 10 | PFIZER INC. ($10,150) |
| 2022 | $26,164 | 25 | PFIZER INC. ($16,013) |
| 2021 | $34,413 | 10 | PFIZER INC. ($11,550) |
| 2020 | $22,231 | 9 | Shionogi Inc ($9,034) |
| 2019 | $44,739 | 40 | Merck Sharp & Dohme Corporation ($31,067) |
| 2018 | $32,893 | 27 | Accelerate Diagnostics Inc. ($13,474) |
| 2017 | $41,125 | 42 | Roche Products Limited ($11,883) |
All Payment Transactions
177 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/13/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $4,387.50 | General |
| 10/07/2024 | La Jolla Pharmaceutical Company | XACDURO (Drug) | Food and Beverage | In-kind items and services | $35.25 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/30/2024 | Shionogi Inc | Fetroja (Drug) | Consulting Fee | Cash or cash equivalent | $5,400.00 | General |
| Category: Infections and Infectious Diseases | ||||||
| 09/30/2024 | Shionogi Inc | Fetroja (Drug) | Travel and Lodging | Cash or cash equivalent | $114.13 | General |
| Category: Infections and Infectious Diseases | ||||||
| 05/21/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $36.71 | General |
| Category: ANTIBIOTIC | ||||||
| 05/19/2024 | AstraZeneca Pharmaceuticals LP | ATACAND (Drug) | Food and Beverage | In-kind items and services | $49.11 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/22/2024 | CSL Behring | — | Travel and Lodging | Cash or cash equivalent | $13,534.02 | General |
| 03/22/2024 | CSL Behring | — | Consulting Fee | Cash or cash equivalent | $10,895.00 | General |
| 03/22/2024 | CSL Behring | — | Travel and Lodging | Cash or cash equivalent | $222.14 | General |
| 03/22/2024 | CSL Behring | — | Travel and Lodging | Cash or cash equivalent | $128.95 | General |
| 03/22/2024 | CSL Behring | — | Food and Beverage | Cash or cash equivalent | $65.02 | General |
| 03/22/2024 | CSL Behring | — | Food and Beverage | Cash or cash equivalent | $27.09 | General |
| 03/22/2024 | CSL Behring | — | Food and Beverage | Cash or cash equivalent | $16.25 | General |
| 03/13/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $2,025.00 | General |
| Category: Infections and Infectious Diseases | ||||||
| 07/24/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,575.00 | General |
| 06/05/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $8,575.00 | General |
| 05/23/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $33.33 | General |
| Category: ANTIBIOTIC | ||||||
| 05/03/2023 | Shionogi Inc | — | Consulting Fee | Cash or cash equivalent | $5,906.25 | General |
| 05/03/2023 | Shionogi Inc | — | Travel and Lodging | Cash or cash equivalent | $268.85 | General |
| 05/03/2023 | Shionogi Inc | — | Travel and Lodging | Cash or cash equivalent | $119.40 | General |
| 05/03/2023 | Shionogi Inc | — | Food and Beverage | In-kind items and services | $64.29 | General |
| 05/03/2023 | Shionogi Inc | — | Food and Beverage | In-kind items and services | $58.30 | General |
| 05/03/2023 | Shionogi Inc | — | Food and Beverage | In-kind items and services | $51.43 | General |
| 05/02/2023 | Shionogi Inc | — | Food and Beverage | In-kind items and services | $111.85 | General |
| 11/13/2022 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $725.70 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PNEUMOCOCCAL CONJ PNG CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 64 | 130 | $73,706 | $20,859 |
| 2022 | 2 | 40 | 91 | $52,156 | $15,238 |
| 2021 | 2 | 51 | 158 | $97,582 | $28,808 |
| 2020 | 2 | 119 | 318 | $188,446 | $57,259 |
Total Patients
274
Total Services
697
Medicare Billing
$122,164
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 34 | 94 | $63,732 | $17,613 | 27.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 18 | 23 | $7,153 | $2,366 | 33.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 13 | $2,821 | $879.58 | 31.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 25 | 65 | $44,070 | $12,934 | 29.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 15 | 26 | $8,086 | $2,303 | 28.5% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 34 | 132 | $89,496 | $26,242 | 29.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 17 | 26 | $8,086 | $2,566 | 31.7% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 65 | 244 | $165,432 | $50,251 | 30.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 54 | 74 | $23,014 | $7,008 | 30.5% |
About Dr. Richard Wunderink, MD
Dr. Richard Wunderink, MD is a Pulmonary Disease healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1639198237.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Wunderink, MD has received a total of $255,265 in payments from pharmaceutical and medical device companies, with $36,936 received in 2024. These payments were reported across 177 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($153,546).
As a Medicare-enrolled provider, Wunderink has provided services to 274 Medicare beneficiaries, totaling 697 services with total Medicare billing of $122,164. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Chicago, IL
- Active Since 07/18/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1639198237
Products in Payments
- Fetroja (Drug) $40,991
- ACCELERATE PHENO (Device) $18,774
- ZERBAXA (Drug) $15,396
- Non-Covered Product (Drug) $12,383
- BioFire FilmArray (Device) $7,446
- PREVNAR - 13 (Biological) $6,400
- GIAPREZA (Drug) $5,667
- Baxdela (Drug) $5,623
- VABOMERE (Drug) $5,389
- Film Array System (Device) $4,760
- XERAVA (Drug) $2,815
- NUZYRA (Drug) $70.04
- ATACAND (Drug) $49.11
- Non-Covered $37.75
- XACDURO (Drug) $35.25
- BREO (Drug) $19.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Chicago
Douglas Hogarth
Pulmonary Disease — Payments: $3.0M
Pulmonary Disease $3.0M
Septimiu Murgu
Pulmonary Disease — Payments: $1.0M
Pulmonary Disease $1.0M
Steven White
Pulmonary Disease — Payments: $685,389
Pulmonary Disease $685,389
Ayodeji Adegunsoye
Pulmonary Disease — Payments: $504,729
Pulmonary Disease $504,729
Brian Garibaldi, M.d, M.D
Pulmonary Disease — Payments: $355,981
Pulmonary Disease $355,981
Dr. Ravi Kalhan, M.d, M.D
Pulmonary Disease — Payments: $327,619
Pulmonary Disease $327,619